Search in:

Advanced search

Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 12

Submit an article Journal homepage

158

Views

CrossRef citations to date

Altmetric

Drug Profile

Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis

Henrik K MathiesenDanish Multiple Sclerosis Center – Neurological Department, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9 Copenhagen 2100, Denmark

Per S SorensenDanish Multiple Sclerosis Center – Neurological Department, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9 Copenhagen 2100, Denmark

Pages 1309-1317 | Published online: 09 Jan 2014

Cite this article
https://doi.org/10.1586/14737175.2013.859523

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 283(5747), 570–572 (1980).
PubMed Web of Science ®Google Scholar
Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J. Neurol. Sci. 60(3), 353–362 (1983).
PubMed Web of Science ®Google Scholar
Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann. Neurol. 21(1), 71–77 (1987).
PubMed Web of Science ®Google Scholar
Bever CT Jr, Young D, Anderson PA et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44(6), 1054–1059 (1994).
PubMed Web of Science ®Google Scholar
Goodman AD, Brown TR, Cohen JA et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 71(15), 1134–1141 (2008).
PubMed Web of Science ®Google Scholar
Goodman AD, Brown TR, Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373(9665), 732–738 (2009).
PubMed Web of Science ®Google Scholar
Goodman AD, Brown TR, Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann. Neurol. 68(4), 494–502 (2010).
PubMed Web of Science ®Google Scholar
Jara M, Barker G, Henney HR 3rd. Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US. Neuropsychiatr. Dis. Treat. 9, 365–370 (2013).
PubMed Web of Science ®Google Scholar
Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 123 (1), 171–184 (2000).
PubMedGoogle Scholar
Wu ZZ, Li DP, Chen SR, Pan HL. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J. Biol. Chem. 284(52), 36453–36461 (2009).
PubMed Web of Science ®Google Scholar
Jeffery DR, Pharr EP. Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis. Core Evid. 5, 107–112 (2010).
PubMedGoogle Scholar
Vollmer T, Blight AR, Henney HR 3rd. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin. Ther. 31(10), 2215–2223 (2009).
PubMed Web of Science ®Google Scholar
Vollmer T, Henney HR 3rd. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. Clin. Ther. 31(10), 2206–2214 (2009).
PubMed Web of Science ®Google Scholar
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability. The 12-item MS walking scale (MSWS-12). Neurology 60(1), 31–36 (2003).
PubMed Web of Science ®Google Scholar
Fernandez O, Berger T, Hartung HP, Putzki N. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. Expert Rev. Clin. Pharmacol. 5(6), 649–665 (2012).
PubMed Web of Science ®Google Scholar
Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult. Scler. 12(5), 594–598 (2006).
PubMed Web of Science ®Google Scholar
Ghezzi A, Montanini R, Basso PF, Zaffaroni M, Massimo E, Cazzullo CL. Epilepsy in multiple sclerosis. Eur. Neurol. 30(4), 218–223 (1990).
PubMed Web of Science ®Google Scholar
Spatt J, Chaix R, Mamoli B. Epileptic and non-epileptic seizures in multiple sclerosis. J. Neurol. 248(1), 2–9 (2001).
PubMed Web of Science ®Google Scholar
Poser CM, Brinar VV. Epilepsy and multiple sclerosis. Epilepsy Behav. 4(1), 6–12 (2003).
PubMed Web of Science ®Google Scholar
Preiningerova JL, Baumhackl U, Csepany T et al. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS). CNS Neurosci. Ther. 19(5), 302–306 (2013).
PubMed Web of Science ®Google Scholar
Goodman AD, Cohen JA, Cross A et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult. Scler. 13(3), 357–368 (2007).
PubMed Web of Science ®Google Scholar
Henney HR 3rd, Faust B, Blight AR. Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers. Am. J. Health Syst. Pharm. 68(22), 2148–2154 (2011).
PubMed Web of Science ®Google Scholar
Smith W, Swan S, Marbury T, Henney H 3rd. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. J. Clin. Pharmacol. 50(2), 151–159 (2010).
PubMed Web of Science ®Google Scholar
Haut SR, Bienen EJ, Miller A. Clinical overview of the seizure risk of dalfampridine. Expert Opin. Drug Saf. 11(4), 651–657 (2012).
PubMed Web of Science ®Google Scholar
March B, Cardi T. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals. Expert Opin. Investig. Drugs 18(12), 1807–1815 (2009).
PubMed Web of Science ®Google Scholar
De Cauwer H, De Wolf P, Couvreur F, Mortelmans L. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol. Belg. 109(1), 40–41 (2009).
PubMed Web of Science ®Google Scholar
Horton L, Conger A, Conger D et al. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology 80(20), 1862–1866 (2013).
PubMed Web of Science ®Google Scholar
Schniepp R, Jakl V, Wuehr M et al. Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report. Mult. Scler. 19(4), 506–508 (2013).
PubMed Web of Science ®Google Scholar
Schmidt S. Fampridine improves severe dysarthria in secondary-progressive multiple sclerosis. Mult. Scler. 19(4), 511 (2013).
PubMed Web of Science ®Google Scholar
Thurtell MJ, Leigh RJ. Treatment of nystagmus. Curr. Treat. Options Neurol. 14(1), 60–72 (2012).
PubMed Web of Science ®Google Scholar
Rossini PM, Pasqualetti P, Pozzilli C et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler. 7(6), 354–358 (2001).
PubMedGoogle Scholar
Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 121(Pt 5), 967–975 (1998).
PubMed Web of Science ®Google Scholar
Smits RC, Emmen HH, Bertelsmann FW, Kulig BM, van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 44(9), 1701–1705 (1994).
PubMed Web of Science ®Google Scholar
Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology 80(16), 1509–1517 (2013).
PubMed Web of Science ®Google Scholar

Websites

ClinicalTrials.gov Identifier:NCT01576354. http://clinicaltrials.gov/show/NCT01576354
Google Scholar
ClinicalTrials.gov Identifier:NCT01597297. http://clinicaltrials.gov/show/NCT01597297
Google Scholar
ClinicalTrials.gov Identifier:NCT01356940. http://clinicaltrials.gov/show/NCT01356940
Google Scholar
ClinicalTrials.gov Identifier:NCT01399957. http://clinicaltrials.gov/show/NCT01399957
Google Scholar
ClinicalTrials.gov Identifier:NCT01480076. http://clinicaltrials.gov/show/NCT01480076
Google Scholar
ClinicalTrials.gov Identifier:NCT01667497. http://clinicaltrials.gov/show/NCT01667497
Google Scholar
ClinicalTrials.gov Identifier:NCT01535664. http://clinicaltrials.gov/show/NCT01535664
Google Scholar
ClinicalTrials.gov Identifier:NCT01444300. http://clinicaltrials.gov/show/NCT01444300
Google Scholar
ClinicalTrials.gov Identifier:NCT01547234. http://clinicaltrials.gov/show/NCT01547234
Google Scholar
ClinicalTrials.gov Identifier:NCT01532154. http://clinicaltrials.gov/show/NCT01532154
Google Scholar
ClinicalTrials.gov Identifier:NCT01468350. http://clinicaltrials.gov/show/NCT01468350
Google Scholar
ClinicalTrials.gov Identifier:NCT01491022. http://clinicaltrials.gov/show/NCT01491022
Google Scholar
ClinicalTrials.gov Identifier:NCT01621113. http://clinicaltrials.gov/show/NCT01621113
Google Scholar
ClinicalTrials.gov Identifier:NCT01446575. http://clinicaltrials.gov/show/NCT01446575
Google Scholar
ClinicalTrials.gov Identifier:NCT01543750. http://clinicaltrials.gov/show/NCT01543750
Google Scholar
ClinicalTrials.gov Identifier:NCT01811706. http://clinicaltrials.gov/show/NCT01811706
Google Scholar
ClinicalTrials.gov Identifier:NCT00041717. http://clinicaltrials.gov/show/NCT00041717
Google Scholar
ClinicalTrials.gov Identifier:NCT01683838. http://clinicaltrials.gov/show/NCT01683838
Google Scholar
ClinicalTrials.gov Identifier:NCT01215084. http://clinicaltrials.gov/show/NCT01215084
Google Scholar
ClinicalTrials.gov Identifier:NCT01645787. http://clinicaltrials.gov/show/NCT01645787
Google Scholar
ClinicalTrials.gov Identifier:NCT01605825. http://clinicaltrials.gov/show/NCT01605825
Google Scholar
ClinicalTrials.gov Identifier:NCT00056810. http://clinicaltrials.gov/show/NCT00056810
Google Scholar
ClinicalTrials.gov Identifier: NCT01480076. http://ClinicalTrials.gov/show/NCT01480076
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis

References

Websites

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis

References

Websites

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date